Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 5CNS 3Sarcoma 2Gastrointestinal 2Dermatologic 2Breast 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Other 1NET 1Genitourinary 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Multiple Endocrine Neoplasia 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leflunomide × Endocrine × Clear all
NCT06540937 2024-08-07

Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
50 enrolled
EndocrineNET

Multiple Endocrine Neoplasia, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡